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Bengt EdvardssonAbstract
Background: Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care
physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance.
Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings
support the efficacy of atenolol in doses of 50 to 200 mg/day.
Methods: Here I present an open-label study the aim of which is to evaluate the efficacy and tolerability of
atenolol (50 mg o.d) for the prevention of CM. 19 patients affected by CM were studied.
Results: Following a one-month run-in period, the patients took atenolol for 3 months. Mean numbers of
headache days per month were reduced from 20.1 ± 2.4 during the run-in period to 7.8 ± 6.1 by month 1.5 and to
7.1 ± 5.7 by the 3rd month of treatment (p < 0.0003). There was a significant difference between 1.5 months and
the 3rd month (p < 0.006). The severity of attacks was reduced from a mean 2.3 ± 0.6 to 1.4 ± 1.1 (p < 0.010) at
1.5 months. In this, there was no difference between 1.5 months and the 3rd month. In 5 (29%) of the17 patients
who completed the study, CM was totally gone during the 3rd month of treatment. No patient was totally
unresponsive to the drug. Among the patients who completed the study, the treatment was well tolerated and the
compliance was good.
Conclusion: Atenolol seems to be a safe and effective treatment for CM. Controlled trials are needed to confirm
the observed results.
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Chronic migraine (CM) is a type of chronic daily headache.
CM presents a challenge to primary care physicians and
neurologists. The overall cost of migraine to society is large
(Hu et al. 1999). Any new treatment showing efficiency is
thus of great importance.
CM was a new addition to the revised International
Classification of Headache Disorders (ICHD) criteria
published in 2004 (Headache Subcommittee of the Inter-
national Headache Society 2004). The criteria for CM
were revised in 2006 and are included in the appendix
of the current classification (Headache Classification
Committee, Olesen et al. 2006). CM patients often re-
quire multiple drugs and nondrug treatment modalities.
The pathophysiology of CM is not clear; however theCorrespondence: Bengt.Edvardsson@med.lu.se
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migraine without aura. The prognosis and treatment of
patients with CM are variable.
Most preventive agents used for CM have not been ex-
amined in well designed double-blind studies (Olesen
et al. 2006). Atenolol is together with other beta-
blockers a first-line choice in episodic migraine prophy-
laxis. Clinical findings support the efficacy of atenolol in
doses of 50 to 200 mg/day (Olesen et al. 2006). Results
from three trials confirm the benefit of atenolol in episodic
migraine prophylaxis. (Stensrud et al. 1980) in their study
found no statistically significant difference between ateno-
lol 50 mg b.i.d. and propranolol 80 mg b.i.d. Atenolol was
more effective than placebo. Another study (Forssman
et al. 1983) reported that the effect of atenolol 100 mg o.d.
was significantly better than that of placebo. Interestingly,
the intake of ergotamine products was significantly lower
in all patients using such drugs. (Johannsson et al. 1987)n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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nificantly better than that of placebo. Few side effects were
reported with both atenolol and placebo. The study
showed atenolol to be safe and effective in the prophylactic
treatment of episodic migraine.
The aim of this open-label study was to evaluate the pos-
sible efficacy and tolerability of atenolol in the prophylaxis
of CM.
Material and methods
For this open-label prospective study a sample of 19 pa-
tients were enrolled, aged 19–32 years (5 M, 14 F). All
patients satisfied the criteria for CM (Headache Classifi-
cation Committee, Olesen et al. 2006). Patients having
the diagnosis CM with medication overuse were excluded.
Patients were consecutively recruited from the Outpatient
department of the Department of Neurology at Skane
University Hospital, Lund.
Inclusion criteria were: initial onset of CM at least
1 year before and patients over 18 years of age. Exclu-
sion criteria were: other headaches but migraine, other
forms of chronic pain, overuse of pain/migraine medica-
tion, psychiatric diseases, neurological diseases and other
chronic diseases, intake of CNS-active medications the
last 3 months before the selection, intake of prophylactic
medication for migraine the last 3 months before the se-
lection, intake of other regular medications, pregnancy
or risk of pregnancy and inability/unwillingness to cooper-
ate. An informed consent was obtained from each partici-
pant. Characteristics of patients enrolled are displayed in
Table 1.
After a one-month run-in period, patients received
atenolol as treatment in a low dose (50 mg o.d.) for
3 months. The inclusion criteria were re-examined at
the end of the run-in period. The patients were free to
take symptomatic medication, if needed. Headache days
per month and severity (rated as: 1, mild; 2, moderate;
and 3, severe) of migraine attacks were recorded by the










Median 3were the main outcome measure and the principal index
used to evaluate the efficacy. Headache days and severity
during the run-in period was compared with what was
found after 1.5 months and during the 3rd month of
therapy. The Wilcoxon signed rank test (a nonparametric
test) was used for the statistical analysis. Differences were
considered significant when P value was less than 0.05. Ad-
verse events were reported during the period.
Results
Two patients out of 19 enrolled left the study because of
adverse events: fatigue and dizziness. 17 patients com-
pleted the treatment period of 3 months. Mean headache
days per month were reduced from 20.1 ± 2.4 during the
run-in period to 7.8 ± 6.1 at 1.5 months and to 7.1 ± 5.7 by
the 3rd month of treatment (p < 0.0003). There was a sig-
nificant difference between 1.5 months and the 3rd month
(p < 0.006) (Figure 1). The severity of attacks was reduced
from mean 2.3 ± 0.6 to 1.4 ± 1.1 (p < 0.010) at 1.5 months.
There were no difference between 1.5 months and the 3rd
month (Figure 2). In 5 (29%) of the17 patients who com-
pleted the study, CM was totally gone at the 3rd month of
treatment. No patient was totally unresponsive to the drug.
No significant adverse effects were reported among the pa-
tients who completed the study. Baseline systolic blood
pressure and heart rate did not differ considerably during
the period. The medication had no effects on activities of
daily living and the patients reported improved quality of
life due to relief of symptoms.
Discussion
This is an open label study made to evaluate the possible
efficacy and tolerability of atenolol in CM. The results in
the study indicate benefit in preventing CM by signifi-
cantly reducing the number of headache days per month
at 1.5 months and in the 3rd month of treatment com-
pared with the run-in period. Atenolol was also able to sig-
nificantly reduce the severity of the attacks at 1.5 months
and in the 3rd month of treatment compared with the
run-in period. To my knowledge, this is the first prospect-
ive study of atenolol as preventive treatment for CM.
The study contradicts earlier results in CM. No beta-
blocker has a Class I study showing effectiveness in redu-
cing CM (Couch 2011). Up to know, only topiramate and
local injections of botulinum toxin have shown efficacy in
large placebo-controlled randomized trials (Couch 2011).
However, these results are in accordance with previous
studies including migraineurs in whom an effect of
prophylactic atenolol has been shown. Beta-blockers are
approximately 50% effective in producing a > 50% re-
duction in attack frequency (Stensrud & Sjaastad 1980;
Forssman et al. 1983; Johannsson et al. 1987; Olesen
et al. 2006). Propranolol is effective in migraine preven-

























Figure 2 Mean (± SD) severity of migraine attacks during the study. (A) and at 1.5 months (B) and month 3 (C).
Edvardsson SpringerPlus 2013, 2:479 Page 3 of 5
http://www.springerplus.com/content/2/1/479
Edvardsson SpringerPlus 2013, 2:479 Page 4 of 5
http://www.springerplus.com/content/2/1/479A Cochrane review of studies 2004 concluded that
propranolol is effective in preventing migraine in the
short term (Barbanti et al. 2011). The relative efficacy
of the different beta-blockers has not been established.
Most studies show no significant difference between
drugs.
The action of beta-blockers is most likely central.
Blockade of β1-mediated effects and consequent inhibition
of Na+ release and tyrosine hydroxylase activity are consid-
ered the main mechanisms of action. Beta-blockers reduce
the neuronal firing rate of noradrenergic neurons of the
locus coeruleus, regulate the firing rate of PAG neurons
and probably interact with the serotonergic system by
blocking 5-HT2C and 5-HT2B receptors. It has been
hypothesized that beta-blockers exert some of their
prophylactic effects in migraine through an action at the
ventroposteromedial thalamic nucleus and inhibition of
cortical spreading depression (Barbanti et al. 2011).
Earlier studies have shown that compared with epi-
sodic migraine, patients suffering from CM are more
likely to be depressed, anxious, suffering from other
forms of chronic pain, and overusing acute pain medica-
tions. Epidemiologic and clinical research consistently
documents an association between depressive, bipolar,
and anxiety disorders with migraine (Diener et al. 2011;
Olesen et al. 2006). All beta-blockers can cause behav-
ioural adverse events as fatigue, lethargy and depression
(Nappi & Moskowitz 2011). Because propranolol may
predispose to depression, its use as an antimigraine pre-
ventive agent is limited (Couch 2011). However, in this
study the subjects showed no signs of depression. The
subjects were young and otherwise healthy. No medica-
tion overuse was found. These facts may have contrib-
uted to the good efficacy results.
Atenolol is associated with risks for pregnant and lactat-
ing women as well as for diabetics. Studies have shown that
women with chronic hypertension that is treated with
atenolol have higher rates of intrauterine growth restriction
and preterm delivery (Orbach et al. 2013). Atenolol is also
associated with significant effects on some nursing infants
and should be given to nursing mothers with caution.
There is one report of hypotension, bradycardia, and cyan-
osis in a breast-fed infant of a mother taking 100 mg daily
(Hutchinson et al. 2013). Beta- blockers are also contrain-
dicated in patients with brittle diabetes mellitus (Olesen
et al. 2006).
Although the patients were observed prospectively,
the study has limitations. It is limited by its small
sample size and open-label nature. The good efficacy
results obtained here must be interpreted with cau-
tion, as they come from an open research in a condi-
tion with a high placebo response. Nevertheless, the
patients were carefully selected and all patients satis-
fied the criteria for CM. In the study, the persistenceof therapeutic effect (29% of patients being headache-free
since the run-in period) can hardly be attributed to a pla-
cebo effect only.
Conclusion
Atenolol seems to be a safe and effective treatment for
CM. Further investigations with double-blind, placebo-
controlled randomized trials would be of value in order
to assess the real efficacy of atenolol as a new thera-
peutic option for preventing CM.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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